Asceneuron awarded USD 2.2 million to advance into phase 1 clinical trials

Asceneuron awarded USD 2.2 million to advance into phase 1 clinical trials

12.3.2021 – The Alzheimer’s Drug Discovery Foundation has awarded Asceneuron USD 2.2 million to conduct a first in human Phase I study of its next-generation O-GlcNAcase inhibitor, ASN51 in healthy subjects and Alzheimer’s patients.

read more on startupticker